Table 3.

Comparison of hepatic and non-hepatic adverse events reported in the first 4 years following market release.

Outcome	Troglitazonea	Rosiglitazoneb
Total reported adverse events (WHO-ART Corrected)	5768	1128
Liver-specific adverse events
Total Deaths*	221	28
Not recovered/not resolved**	8	36
Recovered/resolved with sequelae	134	4
Recovered/resolved	9	30
Unknown	35	27
Not reported	941	155
Total hepatic adverse events	1348	280

*To calculate Total Deaths, MedDRA terms for Death (Event may have contributed), Death (Cause of death other than event), Fatal (Cause of death is event) were added; **WHO controlled vocabulary definitions can be found, e.g. in https://www.who.int/medicines/publications/Pharmaco_TB_web_v2.pdf.

^aTroglitazone adverse events reported from 1998–2001.

^bRosiglitazone adverse events reported from 2000–2003.